Olwen Hahn

5.2k total citations · 3 hit papers
68 papers, 2.9k citations indexed

About

Olwen Hahn is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Olwen Hahn has authored 68 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 35 papers in Oncology and 27 papers in Cancer Research. Recurrent topics in Olwen Hahn's work include Breast Cancer Treatment Studies (17 papers), Advanced Breast Cancer Therapies (12 papers) and Renal cell carcinoma treatment (11 papers). Olwen Hahn is often cited by papers focused on Breast Cancer Treatment Studies (17 papers), Advanced Breast Cancer Therapies (12 papers) and Renal cell carcinoma treatment (11 papers). Olwen Hahn collaborates with scholars based in United States, Canada and Germany. Olwen Hahn's co-authors include Michael J. Morris, Eric J. Small, Susan Halabi, Walter M. Stadler, Daniel J. George, Toni K. Choueiri, Shaker R. Dakhil, Meghara Walsh, M. Dror Michaelson and Joel Picus and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Cancer.

In The Last Decade

Olwen Hahn

68 papers receiving 2.8k citations

Hit Papers

Impact of the Addition of Carboplatin and/or Bevacizumab ... 2014 2026 2018 2022 2014 2017 2023 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
    2014 650 citations William M. Sikov, Donald A. Berry et al. Journal of Clinical Oncology profile →
  2. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
    2017 507 citations Toni K. Choueiri, Susan Halabi et al. Journal of Clinical Oncology profile →
  3. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database
    2023 86 citations Fangyuan Zhao, Nan Chen et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Olwen Hahn United States 23 1.5k 1.5k 1.2k 856 306 68 2.9k
Antoine Thiery-Vuillemin France 24 2.4k 1.6× 2.0k 1.3× 985 0.8× 1.2k 1.4× 449 1.5× 155 3.7k
Anne C. Chiang United States 19 1.2k 0.8× 1.9k 1.3× 682 0.6× 1.1k 1.3× 131 0.4× 88 3.1k
Odd Terje Brustugun Norway 30 1.3k 0.9× 1.4k 1.0× 680 0.6× 1.1k 1.3× 186 0.6× 136 2.9k
Florence Dalenc France 33 1.6k 1.1× 2.6k 1.8× 1.3k 1.1× 1.3k 1.6× 428 1.4× 209 4.5k
Neelima Denduluri United States 23 700 0.5× 1.7k 1.2× 821 0.7× 379 0.4× 367 1.2× 67 2.8k
Timothy Eisen United Kingdom 10 2.0k 1.3× 949 0.6× 1.0k 0.8× 1.8k 2.1× 191 0.6× 17 3.5k
Toshinari Yamashita Japan 24 1.6k 1.1× 1.9k 1.3× 1.1k 0.9× 1.3k 1.5× 211 0.7× 135 3.7k
Giuseppe Procopio Italy 32 3.1k 2.1× 2.7k 1.8× 1.2k 1.0× 1.5k 1.8× 462 1.5× 360 5.2k
Alvaro Moreno‐Aspitia United States 26 664 0.4× 1.9k 1.3× 781 0.6× 632 0.7× 481 1.6× 105 2.7k
Max S. Mano Brazil 22 582 0.4× 1.5k 1.0× 987 0.8× 728 0.9× 353 1.2× 109 2.6k

Countries citing papers authored by Olwen Hahn

Since Specialization
Citations

This map shows the geographic impact of Olwen Hahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olwen Hahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olwen Hahn more than expected).

Fields of papers citing papers by Olwen Hahn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olwen Hahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olwen Hahn. The network helps show where Olwen Hahn may publish in the future.

Co-authorship network of co-authors of Olwen Hahn

This figure shows the co-authorship network connecting the top 25 collaborators of Olwen Hahn. A scholar is included among the top collaborators of Olwen Hahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olwen Hahn. Olwen Hahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Nan, Margarite D. Matossian, Murtuza Rampurwala, et al.. (2025). A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Research and Treatment. 211(1). 111–119. 1 indexed citations
2.
Howard, Frederick M., Nan Chen, Olwen Hahn, et al.. (2024). Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer. Journal of Oncology Pharmacy Practice. 3212339017–3212339017. 1 indexed citations
3.
Hahn, Olwen, et al.. (2023). Adapting a Medical School Cancer Research Education Program to the Virtual Environment: a Mixed-Methods Study. Journal of Cancer Education. 38(5). 1501–1508. 1 indexed citations
4.
Polley, Eric C., Peter H. O’Donnell, Frederick M. Howard, et al.. (2023). Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.. Journal of Clinical Oncology. 41(16_suppl). e12515–e12515. 1 indexed citations
5.
Vannier, Augustin, Fangyuan Zhao, Nan Chen, et al.. (2023). Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 130(8). 1210–1220. 5 indexed citations
6.
Chen, Nan, Murtuza Rampurwala, Sailaja Kamaraju, et al.. (2023). A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.. Journal of Clinical Oncology. 41(16_suppl). e13103–e13103. 3 indexed citations
7.
Chen, Nan, Murtuza Rampurwala, Olwen Hahn, et al.. (2023). Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 1095–1095. 1 indexed citations
8.
Boughey, Judy C., Kari M. Rosenkranz, Karla V. Ballman, et al.. (2023). Abstract GS4-01: Impact of Breast Conservation Therapy on Local Recurrence in Patients with Multiple Ipsilateral Breast Cancer – Results from ACOSOG Z11102 (Alliance). Cancer Research. 83(5_Supplement). GS4–1. 1 indexed citations
9.
Lynce, Filipa, Matthew Blackburn, Christopher Gallagher, et al.. (2021). Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer. 127(19). 3622–3630. 14 indexed citations
10.
Cynthia, X., Vera J. Suman, A. Marilyn Leitch, et al.. (2020). ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.. Journal of Clinical Oncology. 38(15_suppl). 504–504. 27 indexed citations
11.
Fernández-Martínez, Aranzazu, Ian E. Krop, David W. Hillman, et al.. (2020). Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Journal of Clinical Oncology. 38(35). 4184–4193. 70 indexed citations
12.
13.
Urbanic, James J., Xiaofei Wang, Jeffrey A. Bogart, et al.. (2018). Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). International Journal of Radiation Oncology*Biology*Physics. 101(1). 177–185. 32 indexed citations
14.
Lynce, Filipa, Ayesha N. Shajahan‐Haq, Christopher Gallagher, et al.. (2018). PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. Contemporary Clinical Trials Communications. 10. 190–192. 8 indexed citations
15.
Choueiri, Toni K., Susan Halabi, Ben L. Sanford, et al.. (2017). Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology. 35(6). 591–597. 507 indexed citations breakdown →
16.
17.
18.
Ligibel, Jennifer A., William T. Barry, Catherine M. Alfano, et al.. (2017). Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design. npj Breast Cancer. 3(1). 37–37. 61 indexed citations
19.
Sikov, William M., Donald A. Berry, Charles M. Perou, et al.. (2014). Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology. 33(1). 13–21. 650 indexed citations breakdown →
20.
Hahn, Olwen & Ravi Salgia. (2007). Non-Receptor Tyrosine Kinase Inhibitors in Lung Cancer. Anti-Cancer Agents in Medicinal Chemistry. 7(6). 633–642. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Antoine Thiery-Vuillemin Breakdown of academic impact, for papers by Anne C. Chiang Breakdown of academic impact, for papers by Odd Terje Brustugun Breakdown of academic impact, for papers by Florence Dalenc Breakdown of academic impact, for papers by Neelima Denduluri Breakdown of academic impact, for papers by Timothy Eisen Breakdown of academic impact, for papers by Toshinari Yamashita Breakdown of academic impact, for papers by Giuseppe Procopio Breakdown of academic impact, for papers by Alvaro Moreno‐Aspitia Breakdown of academic impact, for papers by Max S. Mano
Rankless by CCL
2026